Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | NQO1 | P15559 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070733 | 0.91 | NQO1 (0.45) | ABCB1NQO1BCHEMAOBABCG2 | |
| SCHEMBL7073297 | 0.91 | MAOB (0.43) | ABCB1TP53MDM2MAOBALOX5 | |
| SCHEMBL7073634 | 0.91 | NQO1 (0.45) | ABCB1NQO1BCHEMAOBABCG2 | |
| SCHEMBL7072240 | 0.88 | ALOX5 (0.50) | ABCB1TP53MDM2ALOX5PTGES | |
| SCHEMBL7067921 | 0.85 | NQO1 (0.49) | ABCB1NQO1TP53MDM2BCHE | |
| SCHEMBL7075613 | 0.85 | MAOB (0.42) | ABCB1NQO1TP53MDM2MAOB | |
| SCHEMBL7067916 | 0.84 | KDM4E (0.46) | MAOBMAOALMNAMAPT | |
| SCHEMBL7070595 | 0.82 | MAOB (0.40) | MAOBMAOALMNAMAPT | |
| SCHEMBL7074913 | 0.82 | LMNA (0.45) | MAOBKCNA3MAOALMNAMAPT | |
| SCHEMBL7072943 | 0.81 | ALDH1A1 (0.41) | ABCB1MAOBMAOALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620842-B2 | Chalcones | INDENA SPA (IT) | 2003-09-16 | — | — | US | claimed |
| EP-1212315-B1 | NOVEL CHALCONES | INDENA SPA (IT) | 2003-03-26 | — | — | EP | claimed |
| US-20030055056-A1 | For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth | INDENA S.P.A. (IT) | 2003-03-20 | — | — | US | claimed |
| EP-1212315-A1 | NOVEL CHALCONES | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | claimed |
| WO-2001017988-A1 | NOVEL CHALCONES | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | claimed |
| US-6620842-B2 | Chalcones | INDENA SPA (IT) | 2003-09-16 | — | — | US | disclosed |
| EP-1212315-B1 | NOVEL CHALCONES | INDENA SPA (IT) | 2003-03-26 | — | — | EP | disclosed |
| US-20030055056-A1 | For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth | INDENA S.P.A. (IT) | 2003-03-20 | — | — | US | disclosed |
| EP-1212315-A1 | NOVEL CHALCONES | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001017988-A1 | NOVEL CHALCONES | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055056-A1 | For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth | HDGF, MKI67, HPD | ABCB1 2714/4885NQO1 1090/4885TP53 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.